What Researchers Did
Researchers conducted a prospective trial to compare the efficacy of intratympanic steroid plus hyperbaric oxygen therapy versus intravenous steroid plus hyperbaric oxygen therapy for idiopathic sudden sensorineural hearing loss.
What They Found
For mild-to-moderate idiopathic sudden sensorineural hearing loss, intratympanic steroid plus hyperbaric oxygen (HBO) therapy resulted in a mean hearing gain of 19 dB and a 78.9% successful treatment rate, compared to 18 dB gain and 70.5% success with intravenous steroid plus HBO. In severe cases, the intratympanic plus HBO group achieved a mean hearing gain of 33 dB and an 81.8% success rate, while the intravenous plus HBO group showed 33.5 dB gain and 58.2% success.
What This Means for Canadian Patients
The study suggests that intratympanic steroid combined with hyperbaric oxygen may offer slightly better success rates, especially for severe hearing loss, compared to intravenous steroids with hyperbaric oxygen. Patients experiencing sudden hearing loss could discuss these treatment options with their audiologists or ENT specialists.
Canadian Relevance
This study was not conducted in Canada and has no direct Canadian connection.
Study Limitations
A limitation of this study is the relatively small sample size within each subgroup, which may affect the generalizability of the findings.